BioSpace News Archive

ANEW MEDICAL, INC. announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW’s Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.

RadNet, Inc. announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Raymond James 45th Annual Institutional Investors Conference in Orlando, Florida today, Monday, March 4, 2024 at 3:25 p.m. Eastern Time.

IDEAYA Biosciences, Inc. announced its participation in upcoming investor relations events.

AbTherx announced expanded commercialization of its bispecific and full human diversity antibody discovery technologies.

Mallinckrodt plc, a global specialty pharmaceutical company, announced that Paul O’Neill has been appointed Executive Vice President, Quality & Operations, Specialty Brands, effective immediately.

Merus N.V. today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 12:00 p.m. ET.

Elixirgen Therapeutics, Inc., today presented preclinical data on its proprietary Bobcat mRNA TM technology in a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking place March 3-6, 2024, in Orlando, Florida.

Ventyx Biosciences, Inc. today announced that it will host a virtual investor event on Monday, March 11, 2024 from 11:00 a.m. to 12:30 p.m. ET.

CymaBay Therapeutics, Inc. announced that the Marketing Authorization Application for seladelpar, for the treatment of primary biliary cholangitis including pruritus in adults without cirrhosis or with compensated cirrhosis who are inadequate responders or intolerant to ursodeoxycholic acid), has been validated and will now be reviewed by the European Medicines Agency.

First Wave BioPharma, Inc., (NASDAQ: FWBI) announced today that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 525,625 shares of the Company’s common stock (or common stock equivalents) at a price of $7.61 per share in a registered direct offering.